Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque Country.

While the numerical differences between groups ranged from 14 to 21 percentage points across timepoints, these differences did not reach statistical significance (week 28: p = 0.09, week 52: p = 0.12, week 76: p = 0.67; chi-squared test), likely owing to the relatively small number of bio-naïve patients ( n = 26 at week 28, n = 19 at week 52, n = 6 at week 76) and the robust efficacy observed in both subgroups.

also in 111,027 other papers